Zacks: Analysts Expect Denali Therapeutics Inc. (NASDAQ:DNLI) to Announce -$0.67 EPS

Wall Street analysts expect that Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) will report earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Denali Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.54) and the lowest estimate coming in at ($0.87). Denali Therapeutics reported earnings of ($0.50) per share in the same quarter last year, which suggests a negative year over year growth rate of 34%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Denali Therapeutics will report full year earnings of ($2.60) per share for the current year, with EPS estimates ranging from ($2.84) to ($2.15). For the next fiscal year, analysts expect that the business will report earnings of ($2.46) per share, with EPS estimates ranging from ($3.07) to ($1.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLI – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Denali Therapeutics had a negative net margin of 597.15% and a negative return on equity of 27.99%. The firm had revenue of $42.10 million for the quarter, compared to the consensus estimate of $33.32 million. During the same quarter last year, the firm earned ($0.58) EPS. The company’s revenue was up 432.9% on a year-over-year basis.

A number of research analysts have recently commented on DNLI shares. Wedbush cut their price target on shares of Denali Therapeutics from $62.00 to $48.00 in a report on Friday. TheStreet cut shares of Denali Therapeutics from a “c-” rating to a “d” rating in a report on Wednesday, March 2nd. Finally, The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating on the stock in a report on Monday, March 7th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $81.67.

DNLI stock opened at $23.05 on Friday. The firm’s fifty day simple moving average is $30.28 and its two-hundred day simple moving average is $38.06. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -9.64 and a beta of 1.90. Denali Therapeutics has a twelve month low of $22.52 and a twelve month high of $79.70.

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the company’s stock in a transaction dated Wednesday, March 23rd. The shares were sold at an average price of $33.83, for a total value of $676,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carole Ho sold 2,918 shares of the stock in a transaction dated Friday, February 11th. The shares were sold at an average price of $34.71, for a total transaction of $101,283.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,210 shares of company stock valued at $1,496,386. 17.00% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. HM Payson & Co. purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $26,000. Lindbrook Capital LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $27,000. Dark Forest Capital Management LP lifted its position in shares of Denali Therapeutics by 19,733.3% during the third quarter. Dark Forest Capital Management LP now owns 595 shares of the company’s stock valued at $30,000 after buying an additional 592 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Denali Therapeutics by 125.3% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 811 shares of the company’s stock valued at $36,000 after buying an additional 451 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Denali Therapeutics during the third quarter valued at about $45,000. 72.32% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Read More